ClinicalTrials.gg

Program

navenibart

Also written as “Navenibart”, “STAR-0215” and “STAR-0215 (SC)”.

Its studies are mostly in Angioedemas, Hereditary, led by BioCryst Pharmaceuticals.

Furthest: phase 3, since Feb 19, 20255 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioCryst Pharmaceuticals53 open or runningphase 3since Feb 19, 2025Jul 26, 2022Dec 2026phase 3 · NCT06842823

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2022First study: phase 1 study in Angioedemas, HereditaryFirst studyNCT05477160 · 41 enrolled · United States
  2. Jan 6, 2023Phase 2 study in Angioedemas, HereditaryNCT05695248 · 29 enrolled · United States, Bulgaria, Canada and more
  3. Aug 17, 2023Phase 2 study in Angioedemas, HereditaryNCT06007677 · 56 enrolled · United States, Bulgaria, Canada and more
  4. Feb 19, 2025Phase 3 study in Angioedemas, HereditaryNCT06842823 · 157 enrolled · United States, Australia, Austria and more
  5. Sep 30, 2025Phase 3 study in Angioedemas, HereditaryNCT07204938 · 145 planned · United States, Brazil, Bulgaria and more

Ahead

  1. Dec 2026Primary completion: phase 3 study in Angioedemas, HereditaryNCT06842823
  2. Mar 2031Primary completion: phase 2 study in Angioedemas, HereditaryNCT06007677
  3. Jun 2031Primary completion: phase 3 study in Angioedemas, HereditaryNCT07204938

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07204938Angioedemas, Hereditary · United States, Brazil, Bulgaria and more3By invitationJun 2031145
NCT06842823Angioedemas, Hereditary · United States, Australia, Austria and more3Active, not recruitingDec 2026157
NCT06007677Angioedemas, Hereditary · United States, Bulgaria, Canada and more2Active, not recruitingMar 203156
NCT05695248Angioedemas, Hereditary · United States, Bulgaria, Canada and more2CompletedMar 13, 202529
NCT05477160Angioedemas, Hereditary · United States1CompletedNov 17, 202341

How it is read

Names in the registry

  • “navenibart”, 2 entries
  • “Navenibart”, 1 entry
  • “STAR-0215”, 1 entry
  • “STAR-0215 (SC)”, 1 entry
  • “STAR-0215 (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.